On September 23, Edward Life Sciences announced that China's State Drug Administration officially approved the addition of three additional mid-valve indications to its SAPIEN 3 transcatheter heart valve system, which can be used for symptomatic heart disease patients due to failure of surgical aortic biological valves, transcatheter aortic biological valves, or surgical mitral valve biovalves as being at high risk of surgery or unsuitable for routine surgery by the cardiac team using a scoring system.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.